U.S. markets closed

  • S&P 500

    4,320.06
    -9.94 (-0.23%)
     

  • Dow 30

    33,963.84
    -106.58 (-0.31%)
     

  • Nasdaq

    13,211.81
    -12.18 (-0.09%)
     

  • Russell 2000

    1,776.50
    -5.32 (-0.30%)
     

  • Crude Oil

    90.33
    +0.70 (+0.78%)
     

  • Gold

    1,944.90
    +5.30 (+0.27%)
     

  • Silver

    23.82
    +0.13 (+0.56%)
     

  • EUR/USD

    1.0647
    -0.0015 (-0.14%)
     

  • 10-Yr Bond

    4.4380
    -0.0420 (-0.94%)
     

  • GBP/USD

    1.2240
    -0.0054 (-0.44%)
     

  • USD/JPY

    148.3600
    +0.7970 (+0.54%)
     

  • Bitcoin USD

    26,554.67
    -97.34 (-0.37%)
     

  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     

  • FTSE 100

    7,683.91
    +5.29 (+0.07%)
     

  • Nikkei 225

    32,402.41
    -168.62 (-0.52%)
     

Silk Road Medical Announces Investor Education Webcast with Key Opinion Leaders

Silk Road Medical
·1 min read
Silk Road Medical
Silk Road Medical

SUNNYVALE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the company will host an investor education webcast at 11:00 a.m. Eastern Time on Thursday, May 25, 2023. The event represents the first in a series of webcasts being organized by the company to educate investors on TCAR and the treatment of carotid artery disease.

The event will include a discussion between Silk Road Medical’s Executive Medical Director, Dr. Sumaira Macdonald, and key opinion leaders in the treatment of carotid artery disease. The event will conclude with an interactive question and answer session. A live and replay version of the webcast will be available at https://investors.silkroadmed.com.

About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com

Media:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com